These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 23931952)
1. Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease. Jenner P Neurol Clin; 2013 Aug; 31(3 Suppl):S17-35. PubMed ID: 23931952 [TBL] [Abstract][Full Text] [Related]
2. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951 [TBL] [Abstract][Full Text] [Related]
3. Rotigotine: the first new chemical entity for transdermal drug delivery. McAfee DA; Hadgraft J; Lane ME Eur J Pharm Biopharm; 2014 Nov; 88(3):586-93. PubMed ID: 25173087 [TBL] [Abstract][Full Text] [Related]
4. The development of the rotigotine transdermal patch: a historical perspective. Waters C Neurol Clin; 2013 Aug; 31(3 Suppl):S37-50. PubMed ID: 23931953 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease. Lyons KE; Pahwa R Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954 [TBL] [Abstract][Full Text] [Related]
6. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. Naidu Y; Chaudhuri KR Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409 [TBL] [Abstract][Full Text] [Related]
7. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome. Splinter MY Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296 [TBL] [Abstract][Full Text] [Related]
8. Treatment of motor and NMS of Parkinson's disease with the rotigotine transdermal system. Lyons KE Neurol Clin; 2013 Aug; 31(3 Suppl):vii-ix. PubMed ID: 23931955 [No Abstract] [Full Text] [Related]
10. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview. Zesiewicz TA; Martinez-Martin P Expert Rev Neurother; 2013 Dec; 13(12):1329-42. PubMed ID: 24236902 [TBL] [Abstract][Full Text] [Related]
11. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993 [TBL] [Abstract][Full Text] [Related]
12. Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease. Steiger M Eur J Neurol; 2008 Jan; 15(1):6-15. PubMed ID: 18042245 [TBL] [Abstract][Full Text] [Related]